| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/JAMA.1987.03400090067035 |
| P698 | PubMed publication ID | 3626001 |
| P50 | author | Philip A Wolf | Q42561276 |
| Ralph B. D'Agostino Sr. | Q59209521 | ||
| William B. Kannel | Q15439387 | ||
| P2093 | author name string | W P Castelli | |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| P1104 | number of pages | 4 | |
| P304 | page(s) | 1183-1186 | |
| P577 | publication date | 1987-09-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Fibrinogen and risk of cardiovascular disease. The Framingham Study. | |
| P478 | volume | 258 |
| Q33633625 | A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo |
| Q37369178 | A common mutation (G-455--> A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study |
| Q40818460 | A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study |
| Q43787052 | A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study |
| Q41847991 | A study of plasma fibrinogen level in type-2 diabetes mellitus and its relation to glycemic control |
| Q30998860 | A systematic comparison of the quality and volume of published data available on novel risk factors for stroke versus coronary heart disease |
| Q73154033 | Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance |
| Q40868635 | Abnormalities of hemostasis in ischemic stroke. |
| Q41596889 | Accelerated atherosclerosis and coronary disease in SLE. |
| Q68752290 | Acute changes in atherogenic and thrombogenic factors with cessation of smoking |
| Q35171257 | Age as a modulator of inflammatory cardiovascular risk factors |
| Q50915833 | Age-related effects of regular physical activity on hemostatic factors in men. |
| Q33791968 | Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes |
| Q33545457 | Aging and cardiovascular disease. Use of subclinical measurements |
| Q35995696 | Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway |
| Q40482679 | An update on coronary risk factors |
| Q36895475 | Angiotensin II induces cell growth and IL-6 mRNA expression through the JAK2-STAT3 pathway in rat cerebellar astrocytes |
| Q38297868 | Angiotensin converting enzyme inhibitors--do they have an anti-ischemic action? |
| Q35113583 | Annual variations in indoor climate in the homes of elderly persons living in Dublin, Ireland and Tromsø, Norway |
| Q34981331 | Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? |
| Q36266057 | Antioxidant status in patients with acute myocardial infarction |
| Q81351174 | Aortic atherosclerosis and stroke |
| Q92740412 | Arrhythmogenic Left Ventricular Cardiomyopathy: A Clinical and CMR Study |
| Q35552716 | Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis |
| Q40430415 | Arterial thrombosis for the clinician. Pathobiology and emerging concepts. |
| Q36965863 | Assessment of coronary heart disease risk by combined analysis of coagulation factors |
| Q35558976 | Association between job characteristics and plasma fibrinogen in a normal working population: a cross sectional analysis in referents of the SHEEP Study. Stockholm Heart Epidemiology Program |
| Q35166181 | Association of antiretroviral therapy with fibrinogen levels in HIV-infection |
| Q80985301 | Association of criteria pollutants with plasma hemostatic/inflammatory markers: a population-based study |
| Q43919582 | Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). |
| Q34568873 | Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the Candidate Gene Association Resource (CARe). |
| Q73940083 | Association of hemostatic factors with peripheral vascular disease |
| Q35413402 | Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status |
| Q37394589 | Association of novel genetic Loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohorts |
| Q74137858 | Association of plasma viscosity and carotid thickening in a French working cohort |
| Q89877488 | Associations of C-reactive protein and fibrinogen with mortality from all-causes, cardiovascular disease and cancer among U.S. adults |
| Q72759440 | Atherogenesis and fibrinogen: historical perspective and current status |
| Q33702808 | Baseline repeated measures from controlled human exposure studies: associations between ambient air pollution exposure and the systemic inflammatory biomarkers IL-6 and fibrinogen |
| Q41996464 | Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. |
| Q40317009 | Bioactive coils cause headache and fever after endovascular treatment of intracranial aneurysms |
| Q36987754 | Biochemical biomarkers are not dependent on physical exercise in patients with spinal cord injury |
| Q37893446 | Biomarkers in chronic kidney disease: a review |
| Q37323794 | Biomarkers related to aging in human populations. |
| Q90649965 | Blood Gene Expression and Vascular Function Biomarkers in Professional Saturation Diving |
| Q44235869 | Blood Rheology and Cardiovascular Risk Factors in Type 1 Diabetes: Relationship with Microalbuminuria |
| Q39294419 | Blood rheology associated with cardiovascular risk factors and chronic cardiovascular diseases: results of an epidemiologic cross-sectional study |
| Q41145943 | Can rheologic variables be of prognostic relevance in arteriosclerotic diseases? |
| Q33649443 | Cardiovascular consequences of polycystic ovary syndrome |
| Q33702516 | Cardiovascular risk determination: discrepancy between total cholesterol evaluation and two compound laboratory indices in Norway |
| Q36970340 | Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis |
| Q35001664 | Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice |
| Q33686005 | Cellular adhesion molecules and atherogenesis |
| Q47119437 | Changes in mediators of inflammation and pro-thrombosis after 12 months of dietary modification in adults with metabolic syndrome |
| Q36369902 | Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease |
| Q57114252 | Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen |
| Q48457643 | Chronobiological patterns of onset of acute cerebrovascular diseases |
| Q48666113 | Classic risk factors, hypercoagulability and migraine in young women with cerebral lacunar infarctions |
| Q41855256 | Classifying Aging As a Disease: The Role of Microbes |
| Q73858936 | Clinical and echocardiographic characteristics of left atrial spontaneous echo contrast in sinus rhythm |
| Q33700673 | Clinical efficacy of raloxifene in postmenopausal women |
| Q40440943 | Clustering of cardiovascular risk factors: Targeting high-risk individuals |
| Q26830210 | Coagulability in obstructive sleep apnea |
| Q35111540 | Cold—an underrated risk factor for health |
| Q35786810 | Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease |
| Q34590848 | Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. |
| Q39645453 | Comparison of an immunochemical assay for plasma fibrinogen and a turbidimetric thrombin clotting technique to discriminate hyperlipidaemic patients from healthy controls |
| Q34630208 | Composition of PM affects acute vascular inflammatory and coagulative markers - the RAPTES project |
| Q37056497 | Considering the inclusion of metabolic and cardiovascular markers in the Panel Study of Income Dynamics |
| Q33911689 | Control of fibrinogen biosynthesis: role of the FFA/albumin ratio |
| Q38737722 | Control of plasma fibrinogen levels |
| Q36679823 | Corticosteroids: do they damage the cardiovascular system? |
| Q39513315 | Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment |
| Q46796548 | Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors |
| Q42020555 | Determinants of disease and disability in the elderly: The Rotterdam elderly study |
| Q34451762 | Diabetes mellitus and coronary heart disease |
| Q38203153 | Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases |
| Q35181453 | Diverging trajectory patterns of systemic versus vascular inflammation over age in healthy Caucasians and African-Americans |
| Q32052986 | Do HMG-CoA reductase inhibitors affect fibrinogen? |
| Q73455432 | Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study |
| Q33613250 | Does weight loss reduce plasma fibrinogen? |
| Q59812375 | Early detection of metabolic dysregulation using water T analysis of biobanked samples |
| Q79566665 | Early-life and adult socioeconomic status and inflammatory risk markers in adulthood |
| Q67752637 | Effect of Renal Replacement Therapy on Viscosity in End-Stage Renal Disease Patients |
| Q34593955 | Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies |
| Q40516350 | Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values |
| Q35876331 | Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk |
| Q47153008 | Effect of post-cessation hyperglycemia on cardiovascular disease and mortality among middle-aged men: an eight-year longitudinal study. |
| Q57822469 | Effect of smoking cessation on the risk of dementia: a longitudinal study |
| Q34106488 | Effects of HMG-CoA reductase inhibitor on hemostasis |
| Q35200997 | Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes |
| Q50721358 | Effects of Nano-zinc on Biochemical Parameters in Cadmium-Exposed Rats. |
| Q35802635 | Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia |
| Q35674511 | Effects of diabetes on the vascular system: current research evidence and best practice recommendations |
| Q41875844 | Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients |
| Q78168514 | Effects of hormone replacement therapy on hemostatic cardiovascular risk factors |
| Q46101255 | Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. |
| Q51298130 | Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women. |
| Q46298577 | Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention |
| Q36872650 | Elevated Levels of Serum Fibrin and Fibrinogen Degradation Products Are Independent Predictors of Larger Coronary Plaques and Greater Plaque Necrotic Core. |
| Q36383775 | Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women |
| Q34786504 | Enigmatic role of lipoprotein(a) in cardiovascular disease |
| Q33701658 | Ethnic differences in risk markers for heart disease in Bradford and implications for preventive strategies |
| Q33738532 | Expanded network of inflammatory markers of atherogenesis: where are we now? |
| Q28220294 | Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review |
| Q35224492 | Fibrin and Its Derivatives in the Normal and Diseased Vessel Wall |
| Q36492191 | Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction |
| Q38117741 | Fibrin(ogen) and thrombotic disease |
| Q92710708 | Fibrin(ogen) in human disease: both friend and foe |
| Q43162739 | Fibrinogen |
| Q72049303 | Fibrinogen and Silent Atherosclerosis in Subjects With Cardiovascular Risk Factors |
| Q37201947 | Fibrinogen and cardiovascular disease |
| Q34118083 | Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). |
| Q35180922 | Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes |
| Q40409553 | Fibrinogen and markers of fibrinolysis and endothelial damage following resolution of critical limb ischaemia |
| Q35729527 | Fibrinogen and mechanisms of thrombosis. A difficult link |
| Q36990172 | Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor |
| Q47363812 | Fibrinogen in obesity before and after weight reduction |
| Q33612628 | Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study |
| Q50907848 | Fibrinogen is an independent marker for thoracic aortic atherosclerosis. |
| Q33591268 | Fibrinogen is related to long-term mortality in Chinese patients with acute coronary syndrome but failed to enhance the prognostic value of the GRACE score |
| Q41094038 | Fibrinogen levels and exercise. Is there a relationship? |
| Q48708426 | Fibrinogen levels and obstructive sleep apnea in ischemic stroke |
| Q51022348 | Fibrinogen levels in women having coronary angiography. |
| Q48207950 | Fibrinogen may mediate the association between long sleep duration and coronary heart disease |
| Q48708439 | Fibrinogen, stroke, and obstructive sleep apnea: an evolving paradigm of cardiovascular risk |
| Q35677944 | Fibrinogen--marker or mediator of vascular disease? |
| Q43265876 | Fibrinogen-dependent signaling in microvascular erythrocyte function: implications on nitric oxide efflux |
| Q42867792 | Fibrinogen: A new cardiovascular risk factor? |
| Q40744822 | Fibrinogen: an important risk factor for atherothrombotic diseases |
| Q35538771 | Fibrinogen: biochemistry, epidemiology and determinants |
| Q40725303 | Fibrinogen: its emerging role as a cardiovascular risk factor |
| Q36598888 | Fibrinolytic activity and clotting factors in ischaemic heart disease in women |
| Q93682385 | Fish oil and plasma fibrinogen |
| Q45757601 | Fish oil and plasma fibrinogen |
| Q57998359 | Frequency distribution of the G/A alleles of the β-fibrinogen gene in the Lebanese population |
| Q43690764 | Fruit and vegetables and cardiovascular risk profile: a diet controlled intervention study |
| Q30352067 | Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots. |
| Q37396336 | Gender differences in the prospective associations of self-reported sleep quality with biomarkers of systemic inflammation and coagulation: findings from the Heart and Soul Study |
| Q53358080 | Gene expression profiling of the short-term adaptive response to acute caloric restriction in liver and adipose tissues of pigs differing in feed efficiency. |
| Q73295903 | Genetic Modulation of Plasma Fibrinogen Concentrations: Possible Importance of Interleukin-6 |
| Q35644256 | Genetic and environmental sources of fibrinogen variability in Israeli families: the Kibbutzim Family Study. |
| Q37768794 | Genetic aspects of ischemic stroke: coagulation, homocysteine, and lipoprotein metabolism as potential risk factors |
| Q40582647 | Genetic determinants of arterial thrombosis |
| Q37777419 | Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk |
| Q34458072 | Genetics of the Framingham Heart Study population |
| Q21261432 | Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study |
| Q35670894 | Gut microbiota and inflammation |
| Q91586511 | Habitual aerobic exercise and circulating proteomic patterns in healthy adults: relation to indicators of healthspan |
| Q34000383 | Haemorrheological abnormalities in unstable angina pectoris: a relation independent of risk factor profile and angiographic severity |
| Q52948768 | Haemostatic and inflammatory alterations in familial hypercholesterolaemia, and the impact of angiotensin II infusion. |
| Q40582669 | Haemostatic function, arterial disease and the prevention of arterial thrombosis |
| Q46351736 | Hemostasis findings in headache and psychosocial stress associated with cerebral ischemia |
| Q43562965 | Hemostatic alterations in patients with acute, unilateral vestibular paresis |
| Q41675668 | Hemostatic concomitants of syndrome X |
| Q44378136 | Hemostatic effects of atorvastatin versus simvastatin |
| Q41047291 | Hemostatic factors as triggers of cardiovascular events. |
| Q41821849 | Heparin as a Therapy for Atherosclerosis: Preliminary Observations on the Intrapulmonary Administration of Low-Dose Heparin in the Morning Versus Evening Gauged by Its Effect on Blood Variables |
| Q36536773 | High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans |
| Q36975186 | Hypercoagulability in dogs with blastomycosis |
| Q37040260 | Hypercoagulable State |
| Q36254845 | Hypercoagulable states and stroke: a selective review. |
| Q37692590 | Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk |
| Q73681235 | Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease |
| Q37197102 | Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease |
| Q86269830 | In vitro oxidation of fibrinogen promotes functional alterations and formation of advanced oxidation protein products, an inflammation mediator |
| Q84705227 | In vivo hemostatic efficacy of polyurethane foam compared to collagen and gelatin |
| Q79079626 | Increased Fibrin Polymerization Rate in Patients with Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus |
| Q73788270 | Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease |
| Q31915357 | Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk |
| Q43908154 | Increased synthesis rate of fibrinogen as a basis for its elevated plasma levels in obese female adolescents |
| Q43952362 | Individual susceptibility to risk factors and implications for prevention |
| Q47869639 | Inflammation and hemostasis in older octogenarians: implication in 5-year survival. |
| Q35549285 | Inflammation-mediated rheumatic diseases and atherosclerosis |
| Q54964445 | Influence of age and normal plasma fibrinogen levels on flow-mediated dilation in healthy adults |
| Q41635547 | Influence of fibrinogen on cardiovascular disease |
| Q51384972 | Insulin resistance is associated with at least threefold increased risk for prothrombotic state in severely obese youngsters. |
| Q37149080 | Iron-induced fibrin in cardiovascular disease |
| Q39285854 | Is increased plasma viscosity a risk factor for high blood pressure? |
| Q71629579 | Is transdermal nicotine associated with cardiovascular risk? |
| Q28382945 | Job strain and cardiovascular risk factors: a cross sectional study of employed Danish men and women |
| Q55652029 | LDL-apheresis: technical and clinical aspects. |
| Q35576140 | Level of fibrinogen and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe |
| Q44021594 | Linkage disequilibrium relationships among four polymorphisms within the human fibrinogen gene cluster |
| Q34457386 | Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program |
| Q37919531 | Lipotoxicity and cardiac dysfunction in mammals and Drosophila |
| Q88594751 | Loneliness in middle age and biomarkers of systemic inflammation: Findings from Midlife in the United States |
| Q51022341 | Long-term influence of fibrinogen on initial and recurrent cardiovascular events in men and women. |
| Q46602143 | Lovastatin Alters Blood Rheology in Primary Hyperlipoproteinemia: Dependence on Lipoprotein(a)? |
| Q67945180 | Markedly increased erythrocyte sedimentation rate, hyperfibrinogenemia, and peripheral vascular disease in diabetic patients: association with clinical implications |
| Q22241929 | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association |
| Q51811716 | Markers of inflammation and hemodynamic measurements in obesity: Copenhagen City Heart Study. |
| Q73438239 | Markers of risk in young offspring with paternal history of myocardial infarction |
| Q38020345 | Mechanism of the antithrombotic effects of fish oil. |
| Q40948177 | Metabolic abnormalities in cardiac ischemia. |
| Q37105071 | Metabolic syndrome and risk factors for cardiovascular disease: are nonagenarians protected? |
| Q30413605 | Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. |
| Q57557608 | Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation |
| Q34820339 | Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia |
| Q41203672 | Modelling the Helsinki Heart Study by means of risk equations obtained from the PROCAM Study and the Framingham Heart Study |
| Q28661433 | Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease |
| Q73808064 | Myocardial ischemia correlates with reduced fibrinolytic activity following peripheral vascular surgery |
| Q38093260 | Neutrophil gelatinase-associated lipocalin as diagnostic and prognostic tool for cardiovascular disease and heart failure |
| Q38854433 | Novel biomarkers of coronary microvascular disease |
| Q33833259 | Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study |
| Q37358924 | Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Women's Genome Health Study |
| Q34186113 | Obesity-related inflammation & cardiovascular disease: efficacy of a yoga-based lifestyle intervention |
| Q35781139 | Obstructive sleep apnoea and stroke |
| Q34086042 | Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms |
| Q47664550 | Outgrowing the laboratory diagnosis of type 1 von Willebrand disease: A two decade study. |
| Q36396260 | Overview of hemostatic factors involved in atherosclerotic cardiovascular disease |
| Q36634243 | Oxidation inhibits iron-induced blood coagulation. |
| Q43244819 | Oxidative modification of fibrinogen affects its binding activity to glycoprotein (GP) IIb/IIIa |
| Q33487898 | Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders |
| Q33740239 | Pathogenesis and pathology of coronary heart disease syndromes |
| Q43812330 | Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of thrombin-activatable fibrinolysis inhibitor |
| Q59796558 | Peripheral Arterial Disease in Type 2 Diabetes Is Associated with an Increase in Fibrinogen Levels |
| Q34373712 | Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation |
| Q40737304 | Physical activity and lipoprotein lipid disorders |
| Q33703587 | Physical activity, physical fitness, blood pressure, and fibrinogen in the Northern Ireland health and activity survey |
| Q58230391 | Physiopathology of Acute Coronary Syndromes |
| Q41047260 | Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events |
| Q81689691 | Plasma fibrinogen - are there age-dependent changes? |
| Q50949758 | Plasma fibrinogen concentration in a Chinese population. |
| Q84934992 | Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention |
| Q46692521 | Plasma fibrinogen levels in Nigerian homozygous (Hb SS) sickle cell patients |
| Q37296049 | Plasma fibrinogen, tissue plasminogen activator, plasminogen activator inhibitor 1, and their related factors in three Japanese population samples |
| Q44215089 | Plasminogen activator inhibitor-1, fibrinogen, and lung function in adolescents with asthma and obesity. |
| Q42566263 | Plasminogen and fibrinogen plasma levels in coronary artery disease |
| Q33770499 | Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications. |
| Q38810790 | Pleiotropic effects of niacin: Current possibilities for its clinical use. |
| Q51950856 | Polyunsaturated fatty acids in depression. |
| Q37518149 | Postinjury hyperfibrinogenemia compromises efficacy of heparin-based venous thromboembolism prophylaxis |
| Q22241923 | Prediction of Coronary Heart Disease Using Risk Factor Categories |
| Q71906135 | Predictive value of hemostatic factors for sudden death in patients with stable angina pectoris |
| Q74315449 | Prevalence of factor V Leiden and prothrombin variant G20210A in patients age <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction |
| Q33857984 | Prevention of coronary heart disease. Part II. Secondary prevention, detection of subclinical disease, and emerging risk factors |
| Q41440536 | Prevention of primary event. Ischemic stroke risk detection and reduction. |
| Q44697395 | Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. |
| Q35690807 | Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited |
| Q33168801 | Procoagulatory changes induced by head-up tilt test in patients with syncope: observational study. |
| Q78512141 | Prognostic value of C-reactive protein, fibrinogen, interleukin-6, and macrophage colony stimulating factor in severe unstable angina |
| Q71270545 | Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial) |
| Q50891002 | Progressive intermittent claudication is associated with impaired fibrinolysis. |
| Q41036094 | Prospective study of endogenous tissue plasminogen activator and risk of stroke |
| Q38074426 | Prosthetic tricuspid valve thrombosis: three case reports and literature review. |
| Q28397769 | Pulmonary and hemostatic toxicity of multi-walled carbon nanotubes and zinc oxide nanoparticles after pulmonary exposure in Bmal1 knockout mice |
| Q52696605 | Purification and characterization of fibrinolytic enzyme from a bacterium isolated from soil. |
| Q35535216 | Purification and characterization of novel fibrinolytic proteases as potential antithrombotic agents from earthworm Perionyx excavatus |
| Q70992308 | Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework |
| Q30912640 | Recent advances in ischaemic heart disease. |
| Q51602431 | Reduced plasma fibrinogen, serum peroxides, lipids, and apolipoproteins after a 3-week vegetarian diet. |
| Q34547749 | Reducing adverse effects of immunosuppressive agents in kidney transplant recipients |
| Q38679335 | Reduction in coronary heart disease: clinical and anatomical considerations |
| Q73318670 | Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men |
| Q35819925 | Relation of fetal and infant growth to plasma fibrinogen and factor VII concentrations in adult life |
| Q32056571 | Relationship of lipoprotein(a) to variables of coagulation in hypertensive subjects |
| Q74202192 | Relative associations of fitness and fatness to fibrinogen, white blood cell count, uric acid and metabolic syndrome |
| Q28384226 | Replication and characterisation of genetic variants in the fibrinogen gene cluster with plasma fibrinogen levels and haematological traits in the Third National Health and Nutrition Examination Survey |
| Q49346082 | Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products |
| Q62760842 | Rheologische Determinanten von Endorgansch�den |
| Q34988616 | Risk factors for venous and arterial thrombosis |
| Q58475992 | Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease |
| Q80577260 | Secondary prevention and referral of elderly patients to a cardiovascular lipid service |
| Q33649621 | Selective estrogen receptor modulators: a look ahead |
| Q82729773 | Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4 |
| Q36683416 | Serum lipids and coronary heart disease in British elderly |
| Q74156319 | Serum lipids, serum insulin, plasma fibrinogen and aerobic capacity in obese and non-obese Singaporean boys |
| Q35258706 | Severity of obstructive sleep apnea is associated with elevated plasma fibrinogen in otherwise healthy patients |
| Q48306073 | Severity of spontaneous echo contrast in the jugular vein associated with ischemic stroke |
| Q64132422 | Shift Work and Biomarkers of Subclinical Cardiovascular Disease: The BCOPS Study |
| Q73265850 | Short- and long-term risk factors for sudden death in patients with stable angina |
| Q38161522 | Should we anticoagulate after bioprosthetic aortic valve replacement? |
| Q44073049 | Six years of treatment with the HELP system of a patient with familial hypercholesterolemia |
| Q35168292 | Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle aged men. |
| Q51388030 | Spontaneous echo contrast in internal jugular veins: a probable indicator for systemic inflammation and a prothrombotic state. |
| Q36768488 | Statins as first-line therapy for acute coronary syndrome? |
| Q37276466 | Statins in the first-line therapy of acute coronary syndrome - similar to aspirin? |
| Q68110060 | Successful modification of medical students' cardiovascular risk factors |
| Q37237136 | Synergistic role of inflammation and insulin resistance as coronary artery disease risk factors in African Americans and Caucasians |
| Q30892742 | The Inflammatory Heart Diseases: Causes, Symptoms, and Treatments |
| Q49424955 | The Potential Role of Senescence As a Modulator of Platelets and Tumorigenesis |
| Q57740621 | The association of chronic cough with the risk of myocardial infarction: the Framingham Heart Study |
| Q41791338 | The association of combined alpha and beta fibrinogen genotype on plasma fibrinogen levels in smokers and non-smokers |
| Q33845784 | The effect of hormone replacement therapy and exercise on cardiovascular disease risk factors in postmenopausal women |
| Q41507873 | The effects of hormone replacement therapy on coronary heart disease |
| Q41728180 | The evidence for exercise-induced inflammation in intermittent claudication: should we encourage patients to stop walking? |
| Q33902971 | The fibrinogen γA/γ' isoform does not promote acute arterial thrombosis in mice |
| Q73485873 | The genetics of haemostasis: a twin study |
| Q37610388 | The hemostatic system through aging and menopause. |
| Q58271154 | The metabolic syndrome and cardiovascular disease |
| Q35786347 | The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury |
| Q39637861 | The pediatrician's role in atherosclerosis prevention |
| Q40802367 | The prevention of cardiovascular disease. Emphasis on secondary prevention. |
| Q37772572 | The role of cold in ischaemic heart disease: a review |
| Q37927179 | The role of intima-media-thickness, ankle-brachial-index and inflammatory biochemical parameters for stroke risk prediction: a systematic review |
| Q51544032 | The role of megestrol acetate as an alternative to conventional hormone replacement therapy. |
| Q40381228 | The role of platelets in essential hypertension |
| Q37789688 | Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention |
| Q44204907 | Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components |
| Q38612491 | Update on stroke risk factors. |
| Q30423046 | Using family-based imputation in genome-wide association studies with large complex pedigrees: the Framingham Heart Study |
| Q53086787 | Value assignment to the WHO 3rd International Standard for Blood Coagulation Fibrinogen Plasma (09/264): communication from the SSC of the ISTH. |
| Q44109228 | Variables associated with fibrinogen in a population-based study: interaction between smoking and age on fibrinogen concentration |
| Q38256564 | Vascular biomarkers in migraine |
| Q47169055 | Water T2 as an early, global and practical biomarker for metabolic syndrome: an observational cross-sectional study |
| Q45335725 | Weekly and yearly rhythms in plasma fibrinogen in hospitalized male military veterans |
| Q30999497 | What explains the increased rate of thromboses among the elderly? Pathophysiological data |
| Q45043945 | White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]) |
| Q78593638 | [Annexin V levels in young patients with acute myocardial infarction: new answers bring new questions] |
| Q74552962 | [C-reactive protein as a coronary risk factor] |
| Q73315343 | [Cardiovascular risk factors in diabetic nephropathy] |
| Q77652795 | [Drug treatment strategies for peripheral obliterative arteriopathy] |
| Q77632173 | [Fibrinogen and monocyte count during the initial phase of ischaemic ictus] |
| Q73303503 | [Ischemic cardiopathy: inflammation markers and the cardiovascular risk] |
| Q95394017 | [Left lower extremity venous thrombosis after operation of cyst in the jaw: a case report] |
| Q68015539 | [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases] |
| Q74451978 | [Prognostic value of fibrinogen in patients admitted with suspected unstable angina and non-q-wave myocardial infarction] |
Search more.